{
    "clinical_study": {
        "@rank": "57068", 
        "arm_group": {
            "arm_group_label": "mesenchymal stem cells", 
            "arm_group_type": "Experimental", 
            "description": "Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem\n      Cells transplantation in hypoxic ischemic encephalopathy."
        }, 
        "brief_title": "Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypoxic Ischemic Encephalopathy", 
        "condition_browse": {
            "mesh_term": [
                "Hypoxia-Ischemia, Brain", 
                "Hypoxia, Brain", 
                "Brain Ischemia", 
                "Ischemia", 
                "Brain Damage, Chronic", 
                "Delirium", 
                "Encephalitis", 
                "Hepatic Encephalopathy", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "To date,hypoxic ischemic encephalopathy is refractory, including after carbon monoxide\n      poisoning, cardiopulmonary resuscitation,hemorrhagic shock and cerebral infarction etc. We\n      used  Mesenchymal Stem Cells via portal vein infusion method to treat hypoxic ischemic\n      encephalopathy. With different durations of follow-up, we cleared therapeutic effect, the\n      quality of life and prognostic implications of the cord blood stem cell infusion on hypoxic\n      ischemic encephalopathy, and evaluated the adverse reactions, through the neurological\n      function score (NIHSS\uff0cBarthel Index), cognitive score (MoCA, MMSE),and the international\n      uniform Parkinson Rating Scale score (UPDRS). Here, we seek new means for the treatment of\n      hypoxic ischemic encephalopathy, and provide the basis for clinical for further application\n      of umbilical cord blood derived Mesenchymal stem cells.\n\n      On the basis of conventional therapy, at the same time, selected patients were given by\n      intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before\n      treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the\n      curative effect. The neurological function score (NIHSS score, Barthel Index) was observed\n      in patients with the ability to live independently and prognosis; MoCA, MMSE were used in\n      the evaluation of cognitive function \uff1bUPDRS was used in the evaluation of extrapyramidal\n      tract function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients are screened foe enrollment in the study if both clinal signs and laboratory\n        tests meet the diagnosis standards recommended by International Classification of\n        Diseases-10 about hypoxic ischemic encephalopathy.\n\n        Exclusion Criteria:\n\n        Exclusion Criteria are any clinically significant diseases in liver,kidney,and heart.\n        additional exclusion criteria are no pregnancy,no immunosuppressive medication, no tumor,\n        no viral diseases or diseases associated with immunodeficiency."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962233", 
            "org_study_id": "12276102D-Neurologic Disorder"
        }, 
        "intervention": {
            "arm_group_label": "mesenchymal stem cells", 
            "description": "Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.\nIntravenous infusion of  umbilical cord derived mesenchymal stem cells", 
            "intervention_name": "mesenchymal stem cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 10, 2013", 
        "location": {
            "contact": {
                "email": "gpwh2000@126.com", 
                "last_name": "Ping Gu, Doctor", 
                "phone": "86-311-85917297"
            }, 
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050031"
                }, 
                "name": "the First Hospital of Hebei Medical University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Efficacy Investigation of Patients With Hypoxic Ischemic Encephalopathy by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells", 
        "overall_contact": {
            "email": "gpwh2000@126.com", 
            "last_name": "Ping Gu, Doctor", 
            "phone": "86-311-85917297"
        }, 
        "overall_official": [
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Baoyong Yan, Doctor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Ping Gu, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Yanyong Wang, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Lina Zhang, Master", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Jun Zhang, Master", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Ethics Committee", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).", 
            "measure": "National Institutes of Health Stroke Scale (NIHSS) scores.", 
            "safety_issue": "No", 
            "time_frame": "180 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962233"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hebei Medical University", 
            "investigator_full_name": "Quanhai Li", 
            "investigator_title": "Director of Cell Thearpy Center, the First Hospital of HeibeiMU", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The Barthel Index measures 10 activities of daily living and mobility. A score of 100  is best (able to live at home with a degree of independence), 0 is worst.", 
                "measure": "The Barthel Index", 
                "safety_issue": "No", 
                "time_frame": "before treatment and post cell transplantation:15,90,180 days"
            }, 
            {
                "description": "The Mini-Mental State Examination (MMSE) is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function.", 
                "measure": "The Mini-Mental State Examination (MMSE)", 
                "safety_issue": "No", 
                "time_frame": "before treatment and post cell transplantation:15,90,180 days"
            }, 
            {
                "description": "The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment.", 
                "measure": "The Montreal Cognitive Assessment(MoCA)", 
                "safety_issue": "No", 
                "time_frame": "before treatment and post cell transplantation:15,90,180 days"
            }, 
            {
                "description": "The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.", 
                "measure": "Unified Parkinson's Disease Rating Scale (UPDRS)", 
                "safety_issue": "No", 
                "time_frame": "before treatment and post cell transplantation:15,90,180 days."
            }, 
            {
                "description": "adverse reaction include temperature changes,the change of blood pressure,anaphylaxis,seizure,renal dysfunction,or hepatic injury by monitoring blood routine, urinalysis, ALT,AST,Urea,Crea and electrocardiogram etc.", 
                "measure": "adverse reaction", 
                "safety_issue": "Yes", 
                "time_frame": "post cell transplantation:15,90,180 days"
            }
        ], 
        "source": "Hebei Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}